Jean Kaseya & Gilead Sciences

Jean Kaseya: Jean Kaseya, Director General of United States — Centers for Disease Control and Prevention, emphasized the need for rapid regional coordination to contain the Ebola outbreak due to high population movement between affected areas and neighboring countries.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Jean Kaseya: Jean Kaseya>>>, director-general of the Africa CDC, has expressed

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.

Jean Kaseya: Africa CDC Director-General called for intensified efforts to stop the outbreak.

Gilead Sciences: Developed obeldesivir, the antiviral being tested in the EBO-PEP trial.

Jean Kaseya: Jean Kaseya, Director-General of the United States — Centers for Disease Control and Prevention, expects the number of Ebola cases to increase with more rigorous surveillance and believes a vaccine for the Bundibugyo strain will be ready by year-end.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

Jean Kaseya: Africa CDC Director General; called for $16 million funding for trials.

Gilead Sciences: Supplying remdesivir for clinical trials; potential positive impact if treatment proves effective.